Trial Profile
A Long-term Access Programme for Subjects With Severe Asthma Who Participated in a GSK-sponsored Mepolizumab Clinical Study
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 Mar 2023
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Expanded access
- Sponsors GlaxoSmithKline; GSK
- 14 Mar 2023 This trial has been completed in Bulgaria (End Date: 31 Aug 2022), according to European Clinical Trials Database record.
- 24 Dec 2022 This trial has been completed in Poland(End Date: 31 Aug 2022), according to European Clinical Trials Database record
- 19 Dec 2022 This trial has been completed in Greece (End Date: 31 Aug 2022), according to European Clinical Trials Database record.